Genetically Inspired Prognostic Scoring System (GIPSS) for Primary Myelofibrosis (PMF)
Assesses the prognosis of primary myelofibrosis based solely on genomic markers.
Advice
- Utilize results in conjunction with clinical judgment and patient preference to guide management care plans and inform goals of care and outcome discussions.
- Combine results with more comprehensive prognostic tools to enhance risk stratification and treatment decisions, particularly for individuals in the intermediate-1 or intermediate-2 categories.
- High-risk patients, especially young individuals with good functional status, may benefit from more aggressive treatments, such as allogeneic stem cell transplantation.
- Low-risk patients may opt for conservative treatments without aggressive interventions.